Jiang et al. [177] designed and synthesized a series of high-potency peptidomimetics (for a total of 50 peptidomimetic inhibitors), that efficiently blocked the interaction between adenomatous-polyposis-coli (APC) and its receptor Asef, both in vitro and in colorectal cancer cells. Here, APC is linked to colorectal cancer.